JPWO2020106642A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020106642A5 JPWO2020106642A5 JP2021527206A JP2021527206A JPWO2020106642A5 JP WO2020106642 A5 JPWO2020106642 A5 JP WO2020106642A5 JP 2021527206 A JP2021527206 A JP 2021527206A JP 2021527206 A JP2021527206 A JP 2021527206A JP WO2020106642 A5 JPWO2020106642 A5 JP WO2020106642A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 150000003839 salts Chemical class 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 4
- -1 1,2-dihydroxyethyl Chemical group 0.000 claims 3
- 108010054147 Hemoglobins Proteins 0.000 claims 3
- 102000001554 Hemoglobins Human genes 0.000 claims 3
- 108010016797 Sickle Hemoglobin Proteins 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769196P | 2018-11-19 | 2018-11-19 | |
| US62/769,196 | 2018-11-19 | ||
| US201962821314P | 2019-03-20 | 2019-03-20 | |
| US62/821,314 | 2019-03-20 | ||
| US201962848773P | 2019-05-16 | 2019-05-16 | |
| US62/848,773 | 2019-05-16 | ||
| US201962883313P | 2019-08-06 | 2019-08-06 | |
| US62/883,313 | 2019-08-06 | ||
| PCT/US2019/062054 WO2020106642A1 (en) | 2018-11-19 | 2019-11-18 | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022509091A JP2022509091A (ja) | 2022-01-20 |
| JPWO2020106642A5 true JPWO2020106642A5 (https=) | 2023-07-26 |
| JP2022509091A5 JP2022509091A5 (https=) | 2023-07-26 |
| JP7509772B2 JP7509772B2 (ja) | 2024-07-02 |
Family
ID=68848454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527206A Active JP7509772B2 (ja) | 2018-11-19 | 2019-11-18 | ヘモグロビンのモジュレーター |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10683285B2 (https=) |
| EP (2) | EP3880654B1 (https=) |
| JP (1) | JP7509772B2 (https=) |
| KR (1) | KR102842589B1 (https=) |
| CN (1) | CN113316568B (https=) |
| AU (1) | AU2019383960B2 (https=) |
| BR (1) | BR112021007044B1 (https=) |
| CA (1) | CA3120380A1 (https=) |
| CO (1) | CO2021007993A2 (https=) |
| CR (1) | CR20210335A (https=) |
| CY (1) | CY1125025T1 (https=) |
| DK (1) | DK3880654T3 (https=) |
| ES (1) | ES2908325T3 (https=) |
| HR (1) | HRP20220295T1 (https=) |
| HU (1) | HUE057323T2 (https=) |
| IL (1) | IL283128B2 (https=) |
| LT (1) | LT3880654T (https=) |
| MA (1) | MA54231B1 (https=) |
| MD (1) | MD3880654T2 (https=) |
| MX (1) | MX2021005887A (https=) |
| PL (1) | PL3880654T3 (https=) |
| PT (1) | PT3880654T (https=) |
| RS (1) | RS62970B1 (https=) |
| SA (1) | SA521422031B1 (https=) |
| SG (1) | SG11202104705RA (https=) |
| SI (1) | SI3880654T1 (https=) |
| SM (1) | SMT202200106T1 (https=) |
| TW (1) | TWI841630B (https=) |
| WO (1) | WO2020106642A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX379235B (es) | 2013-03-15 | 2025-03-11 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014150258A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| BR112022019423A2 (pt) * | 2020-03-31 | 2022-12-06 | Global Blood Therapeutics Inc | Moduladores de hemoglobina |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| JP2024520896A (ja) | 2021-05-14 | 2024-05-27 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンのモジュレーターを作製する方法 |
| EP4337659A1 (en) * | 2021-05-14 | 2024-03-20 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
| US20240316184A1 (en) | 2021-07-19 | 2024-09-26 | Bioapplications Inc. | Plant-based covid-19 variant recombinant spike protein expression vector and recombinant protein using same |
| EP4444285A1 (en) * | 2021-12-10 | 2024-10-16 | Global Blood Therapeutics, Inc. | Methods of administering a modulator of hemoglobin |
| EP4727555A1 (en) | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
| WO2025262596A1 (en) * | 2024-06-20 | 2025-12-26 | Pfizer Inc. | Methods of making osivelotor |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| ZW14480A1 (en) | 1979-06-29 | 1982-03-17 | Wellcome Found | Pharmaceutical ethers preparation use and intermediates therefore and their preparation |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| IT1193786B (it) | 1980-12-18 | 1988-08-24 | Wellcome Found | Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63258463A (ja) | 1987-04-14 | 1988-10-25 | Kumiai Chem Ind Co Ltd | ２−フエノキシピリミジン誘導体及び除草剤 |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| EP0658559A1 (de) | 1993-12-14 | 1995-06-21 | Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. | Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren |
| YU41801A (sh) | 1998-12-14 | 2003-12-31 | F. Hofman - La Roche Ag. | Derivati fenilglicina |
| US6472349B1 (en) | 1999-03-31 | 2002-10-29 | Basf Aktiengesellschaft | Pyridine-2,3-dicarboxylic acid diamides |
| MXPA05001544A (es) | 2002-08-08 | 2005-04-19 | Smithkline Beecham Corp | Compuestos de tiofeno. |
| CA2507545C (en) | 2002-12-04 | 2011-06-21 | Virginia Commonwealth University | Use of furfural derivatives as anti-sickling agents |
| BRPI0411255A (pt) | 2003-06-12 | 2006-08-01 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
| JP2007534691A (ja) | 2004-04-22 | 2007-11-29 | アロス・セラピューティクス・インコーポレーテッド | アロステリックヘモグロビン修飾体の組成物および前記組成物の製造法 |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| CN100562514C (zh) | 2005-07-22 | 2009-11-25 | 中国科学院上海药物研究所 | 一类取代丙酰胺衍生物、其制备方法和用途 |
| WO2008066145A1 (en) | 2006-11-30 | 2008-06-05 | R-Tech Ueno, Ltd. | Thiazole derivative and use thereof as vap-1 inhibitor |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| WO2009136889A1 (en) | 2008-05-08 | 2009-11-12 | Nova Southeastern University | Specific inhibitors for vascular endothelial growth factor receptors |
| GB0811451D0 (en) | 2008-06-20 | 2008-07-30 | Syngenta Participations Ag | Novel microbiocides |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| ES2643403T3 (es) | 2011-12-28 | 2017-11-22 | Global Blood Therapeutics, Inc. | Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20150057251A1 (en) | 2013-08-26 | 2015-02-26 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MX379235B (es) * | 2013-03-15 | 2025-03-11 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| WO2014150289A1 (en) * | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140271591A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2015031284A1 (en) | 2013-08-26 | 2015-03-05 | Global Blood Therapeutics, Inc. | Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s) |
| US20160207904A1 (en) | 2013-08-27 | 2016-07-21 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| US20150141465A1 (en) | 2013-11-18 | 2015-05-21 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US9248199B2 (en) | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
-
2019
- 2019-11-18 PT PT198184012T patent/PT3880654T/pt unknown
- 2019-11-18 SG SG11202104705RA patent/SG11202104705RA/en unknown
- 2019-11-18 BR BR112021007044-3A patent/BR112021007044B1/pt active IP Right Grant
- 2019-11-18 ES ES19818401T patent/ES2908325T3/es active Active
- 2019-11-18 HR HRP20220295TT patent/HRP20220295T1/hr unknown
- 2019-11-18 EP EP19818401.2A patent/EP3880654B1/en active Active
- 2019-11-18 LT LTEPPCT/US2019/062054T patent/LT3880654T/lt unknown
- 2019-11-18 AU AU2019383960A patent/AU2019383960B2/en active Active
- 2019-11-18 IL IL283128A patent/IL283128B2/en unknown
- 2019-11-18 WO PCT/US2019/062054 patent/WO2020106642A1/en not_active Ceased
- 2019-11-18 MD MDE20210907T patent/MD3880654T2/ro unknown
- 2019-11-18 US US16/687,474 patent/US10683285B2/en active Active
- 2019-11-18 MX MX2021005887A patent/MX2021005887A/es unknown
- 2019-11-18 RS RS20220126A patent/RS62970B1/sr unknown
- 2019-11-18 HU HUE19818401A patent/HUE057323T2/hu unknown
- 2019-11-18 SI SI201930191T patent/SI3880654T1/sl unknown
- 2019-11-18 CR CR20210335A patent/CR20210335A/es unknown
- 2019-11-18 PL PL19818401T patent/PL3880654T3/pl unknown
- 2019-11-18 KR KR1020217018851A patent/KR102842589B1/ko active Active
- 2019-11-18 MA MA54231A patent/MA54231B1/fr unknown
- 2019-11-18 DK DK19818401.2T patent/DK3880654T3/da active
- 2019-11-18 EP EP21217304.1A patent/EP4046988A1/en active Pending
- 2019-11-18 SM SM20220106T patent/SMT202200106T1/it unknown
- 2019-11-18 TW TW108141848A patent/TWI841630B/zh active
- 2019-11-18 CN CN201980088809.5A patent/CN113316568B/zh active Active
- 2019-11-18 CA CA3120380A patent/CA3120380A1/en active Pending
- 2019-11-18 JP JP2021527206A patent/JP7509772B2/ja active Active
-
2020
- 2020-05-04 US US16/865,625 patent/US11548880B2/en active Active
-
2021
- 2021-05-17 SA SA521422031A patent/SA521422031B1/ar unknown
- 2021-06-18 CO CONC2021/0007993A patent/CO2021007993A2/es unknown
-
2022
- 2022-02-28 CY CY20221100163T patent/CY1125025T1/el unknown
- 2022-11-21 US US17/991,448 patent/US20230159507A1/en active Pending
-
2025
- 2025-12-16 US US19/421,948 patent/US20260103454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020106642A5 (https=) | ||
| EP4438122A2 (en) | Ring-modified proline short peptide compound and use thereof | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2021514001A5 (https=) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| WO2004012648A2 (de) | Substituierte diarylheterocyclen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| RU2007124681A (ru) | Производные тетрагидропирана в качестве противодиабетических средств | |
| DE602004001864T2 (de) | Verbindungen und methoden zur behandlung von proliferativen krankheiten, retinopathie und arthritis | |
| CN107848952B (zh) | 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用 | |
| EP1861361A1 (en) | Glycopyrronium salts and their therapeutic use | |
| JPWO2022256434A5 (https=) | ||
| JPWO2022212489A5 (https=) | ||
| JPWO2020041741A5 (https=) | ||
| EP4201941A1 (en) | Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof | |
| CN103476769B (zh) | 抗癌剂 | |
| JPWO2021143706A5 (https=) | ||
| JPWO2020232156A5 (https=) | ||
| JPWO2020252383A5 (https=) | ||
| JPWO2022195454A5 (https=) | ||
| JPWO2023078231A5 (https=) | ||
| US20240158373A1 (en) | Ring-modified proline short peptide compound and use thereof | |
| JPWO2023077040A5 (https=) | ||
| JPH03291261A (ja) | ω−アミノ−フェニルアルカノニトリル誘導体 | |
| JPWO2023107563A5 (https=) | ||
| US7956039B2 (en) | Use of amygdalin analogues for the treatment of psoriasis |